111 related articles for article (PubMed ID: 21601175)
21. [The morphological forms of malignant uveal melanoma].
Simionescu C
Oftalmologia; 1993; 37(1):3-11. PubMed ID: 8507607
[TBL] [Abstract][Full Text] [Related]
22. Clinical predictors of survival in metastatic uveal melanoma.
Lorenzo D; Piulats JM; Ochoa M; Arias L; Gutiérrez C; Català J; Cobos E; Garcia-Bru P; Dias B; Padrón-Pérez N; Caminal JM
Jpn J Ophthalmol; 2019 Mar; 63(2):197-209. PubMed ID: 30796549
[TBL] [Abstract][Full Text] [Related]
23. Optic nerve invasion of uveal melanoma: clinical characteristics and metastatic pattern.
Lindegaard J; Isager P; Prause JU; Heegaard S
Invest Ophthalmol Vis Sci; 2006 Aug; 47(8):3268-75. PubMed ID: 16877391
[TBL] [Abstract][Full Text] [Related]
24. No differences in outcome between radical surgical treatment (enucleation) and stereotactic radiosurgery in patients with posterior uveal melanoma.
Furdova A; Slezak P; Chorvath M; Waczulikova I; Sramka M; Kralik G
Neoplasma; 2010; 57(4):377-81. PubMed ID: 20429631
[TBL] [Abstract][Full Text] [Related]
25. Metastatic melanoma in the eye and orbit.
Zografos L; Ducrey N; Beati D; Schalenbourg A; Spahn B; Balmer A; Othenin-Girard CB; Chamot L; Egger E
Ophthalmology; 2003 Nov; 110(11):2245-56. PubMed ID: 14597536
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic inactivation of RASSF1a in uveal melanoma.
Maat W; van der Velden PA; Out-Luiting C; Plug M; Dirks-Mulder A; Jager MJ; Gruis NA
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):486-90. PubMed ID: 17251440
[TBL] [Abstract][Full Text] [Related]
27. Survival rates with uveal melanoma in the United States: 1973-1997.
Singh AD; Topham A
Ophthalmology; 2003 May; 110(5):962-5. PubMed ID: 12750098
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up after uveal melanoma charged particle therapy.
Char DH; Kroll SM; Castro J
Trans Am Ophthalmol Soc; 1997; 95():171-87; discussion 187-91. PubMed ID: 9440169
[TBL] [Abstract][Full Text] [Related]
29. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
[TBL] [Abstract][Full Text] [Related]
30. Posterior uveal melanoma in young patients treated with proton beam therapy.
Vavvas D; Kim I; Lane AM; Chaglassian A; Mukai S; Gragoudas E
Retina; 2010 Sep; 30(8):1267-71. PubMed ID: 20224468
[TBL] [Abstract][Full Text] [Related]
31. Molecular pathways mediating liver metastasis in patients with uveal melanoma.
Bakalian S; Marshall JC; Logan P; Faingold D; Maloney S; Di Cesare S; Martins C; Fernandes BF; Burnier MN
Clin Cancer Res; 2008 Feb; 14(4):951-6. PubMed ID: 18281525
[TBL] [Abstract][Full Text] [Related]
32. Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study.
Mallikarjuna K; Pushparaj V; Biswas J; Krishnakumar S
Curr Eye Res; 2007 Mar; 32(3):281-90. PubMed ID: 17453948
[TBL] [Abstract][Full Text] [Related]
33. HLA Class I and II genotype in uveal melanoma: relation to occurrence and prognosis.
Maat W; Haasnoot GW; Claas FH; Schalij-Delfos NE; Schreuder GM; Jager MJ
Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):3-6. PubMed ID: 16384937
[TBL] [Abstract][Full Text] [Related]
34. Survival after proton-beam irradiation of uveal melanomas.
Kodjikian L; Roy P; Rouberol F; Garweg JG; Chauvel P; Manon L; Jean-Louis B; Little RE; Sasco AJ; Grange JD
Am J Ophthalmol; 2004 Jun; 137(6):1002-10. PubMed ID: 15183783
[TBL] [Abstract][Full Text] [Related]
35. Invited commentary. Uveal melanoma: implications of tumor doubling time.
O'Brien J
Ophthalmology; 2001 May; 108(5):831-2. PubMed ID: 11780648
[No Abstract] [Full Text] [Related]
36. [The hierarchization of the prognostic factors in uveal malignant melanoma].
Călugăru M; Mera M; Călugăru D
Oftalmologia; 2000; 50(1):30-4. PubMed ID: 11021104
[TBL] [Abstract][Full Text] [Related]
37. Mortality after uveal and conjunctival melanoma: which tumour is more deadly?
Kujala E; Tuomaala S; Eskelin S; Kivelä T
Acta Ophthalmol; 2009 Mar; 87(2):149-53. PubMed ID: 18937804
[TBL] [Abstract][Full Text] [Related]
38. 125I plaque therapy for uveal melanoma. Analysis of the impact of time and dose factors on local control.
Quivey JM; Augsburger J; Snelling L; Brady LW
Cancer; 1996 Jun; 77(11):2356-62. PubMed ID: 8635107
[TBL] [Abstract][Full Text] [Related]
39. What is the significance of vortex vein invasion in uveal melanoma?
Raoof N; Rennie IG; Salvi SM; Sisley K; Caine A; Mudhar HS
Eye (Lond); 2009 Aug; 23(8):1661-7. PubMed ID: 19011609
[TBL] [Abstract][Full Text] [Related]
40. Proton beam radiotherapy for uveal melanomas at nice teaching hospital: 16 years' experience.
Caujolle JP; Mammar H; Chamorey E; Pinon F; Herault J; Gastaud P
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):98-103. PubMed ID: 19910136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
